Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NS2 · ADX-102, ALD-102

Small molecule · developed by Aldeyra Therapeutics

Phase 2 Most advanced trial (none active)

ALDX Developer

2 Registered trials

What is NS2?

NS2 is an ophthalmic drop formulation at 0.5% strength. It is studied in non-infectious anterior uveitis, allergic conjunctivitis and seasonal allergies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADX-102, ALD-102
Drug type: Small molecule
Therapy area: Immunology, Ophthalmology
Developer: Aldeyra Therapeutics, Inc. (ALDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: F0GIZ22IJH

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02578914	Phase 2	Allergic Conjunctivitis	Completed	ALDX
NCT02406209	Phase 2	Non-infectious Anterior Uveitis	Completed	ALDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic ConjunctivitisNon-infectious Anterior UveitisSeasonal Allergies

More from Aldeyra Therapeutics

ADX-629 Phase 2 Reproxalap Phase 3

Sources

ClinicalTrials.gov NCT02406209

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALDX page.

Follow ALDX, the company behind NS2

See ALDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z